A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 1, 2008, Pages 29-33

  Zhang, Xiaodong ^a   Shen, Lin ^a   Li, Jie ^a   Li, Yan ^a   Li, Jian ^a   Jin, Maolin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Chemotherapy; Cisplatin; Paclitaxel; Squamous cell carcinoma of the esophagus

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANALGESIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL TOXICITY; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; LUNG TOXICITY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PROBABILITY; RASH; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; BONE TUMOR; ESOPHAGUS TUMOR; FOLLOW UP; LIVER TUMOR; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; SURVIVAL RATE;

EID: 42449161955     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181131ca9     Document Type: Article

References (25)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16:1826-1834.
3. Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992; 22:172-176.
4. Polee MB, Kok TC, Siersema PD, et al. Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the esophagus. Anticancer Drugs. 2001;12:513-517.
5. Adelstein DJ, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol. 2000;18:2032-2039.
6. Kollmannsberger C, Quietzsch D, Haag C, et al. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer. 2000;83:458-462.
7. Polee MB, Eskens FA, van der Burg ME, et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer. 2002;86:669-673.
8. Brenner B, Ilson DH, Minsky BD, et al. Phase I trial of combined modality therapy for localized esophageal cancer:Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol. 2004;22:45-52.
9. El-Rayes BF, Shields A, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol. 2004;15:960-965.
10. Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86:1086-1091.
11. Rowinsky EK, Citardi MJ, Noe DA, et al. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol. 1993;119:727-733.
12. Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev. 2003;29:525-532.
13. Millikan KW, Silverstein J, Hart V, et al. A 15-year review of esophagectomy for carcinoma of the esophagus and cardia. Arch Surg. 1995; 130:617-624.
14. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216-1220.
15. Levard H, Pouliquen X, Hay JM, et al. 5-Fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma. A multicentre randomised controlled trial. The French Associations for Surgical Research. Eur J Surg. 1998;164:849-857.
16. Spiridonidis CH, Laufman LR, Jones JJ, et al. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer. 1996;78:2070-2077.
17. Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002;94:641-646.
18. Conroy T, Etienne PL, Adenis A, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol. 2002;13:721-729.
19. van der Gaast A, Kok TC, Vos R, et al. A phase I dose finding study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer. Semin Oncol. 1997;24:82-85.
20. Ajani JA. Treatment of patients with upper gastrointestinal carcinomas. Semin Oncol. 1997;24:1972-1976.
21. Ajani JA, Ilson DH, Daugherty K, Kelsen DP. Paclitaxel in the treatment of carcinoma of the esophagus. Semin Oncol. 1995;22:35-40.
22. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer. 1994;69:299-306.
23. Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J. 2000;6:316-323.
24. Kelsen D, Ginsberg R, Bains M, et al. A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report. Semin Oncol. 1997;24:1977-1981.
25. Polee MB, Tilanus HW, Eskens FA, et al. Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Ann Oncol. 2003;14:1253-1257.